The annual survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly. Photo via Getty Images

Few studies gauge the barometric pressure of the Bayou City like the Kinder Houston Area Survey.

Designed to take the temperature of the general population, the study — now in its 40th year — reveals a Houston citizenry optimistic about its personal futures, per the report.

A little about the study before delving in: The report was conducted by the esteemed Stephen Klineberg, founding director of Rice University's Kinder Institute for Urban Research and emeritus professor of sociology; and Robert Bozick, senior research fellow at the Kinder Institute.

This new survey was unveiled at the Kinder Institute's "Lunch-Out" recent virtual event. Interviews of some 1,051 Harris County adults were conducted between January 18 and March 29 by the National Opinion Research Center at the University of Chicago.

The full report is available online.

The No. 1 concern

Public health concerns, while rarely registering in previous surveys, were cited as the biggest problem facing Houstonians this year, according to a press release. Some 25 percent of respondents cited the pandemic or health-related issues.

Others — 20 percent — pointed to the economy as the biggest problem, that's up from 13 percent last year. Only 14 percent cited crime, and traffic dropped to 13 percent, down from 30 percent last year.

Highlighting a national socioeconomic disparity, 58 percent of Blacks and 66 percent of Hispanics said they had to risk exposure to the coronavirus to keep their jobs during the past year, per the report. That's compared to 41 percent of Asians and only 36 percent of whites.

Additionally, the report notes that Blacks and Hispanics were more likely (at 73 percent and 67 percent, respectively) to know someone who was hospitalized with or died as a result of having COVID-19, compared with whites (57 percent) and Asians (40 percent).

Mental health issues have arisen as a serious problem in equal numbers across ethnic communities. More than 50 percent of respondents — in all four groups — reported feeling more stress and experiencing more emotional problems during the past year, compared with 2020.

Jobs and the economy

Though Houston is an opportunity city, the Kinder Survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly, to 61 percent this year from 68 percent in 2020.

A mere 21 percent reported their economic situations were getting better, down from 34 percent in 2020. Notably — for the first time in the 40 years — of the survey, more respondents (25 percent) said their financial situations were getting worse than getting better.

Blacks and Hispanics were also more likely than Asians and whites to have experienced a loss of income and to have received help from government programs in the past year.

Race relations, immigration, and inequity

Positive ratings of relations among ethnic groups in the Houston area declined across the board, especially among Blacks. Whites and Hispanics were significantly more likely than in previous years to agree that Blacks are still a long way from having the same opportunities in life as whites.

The number of people who said the criminal justice system is biased against Blacks increased to 54 percent from 32 percent in 2015, when the question was last asked, per a release.

Weather, religion, and politics

Area residents were less likely than in previous surveys to say it's virtually certain the region will experience more severe storms in coming years (59 percent in 2021, compared with 81 percent in 2018 and 2020).

The number of religious Houstonians continues to decline, with more people than ever indicating they are not part of any faith tradition (22 percent today, compared with 8 percent in 2008) and do not consider religion to be an important part of their lives (26 percent, compared with 10 percent in 2008), per the study.

Meanwhile, 45 percent of those surveyed said they felt closer to the Democratic Party this year, while only 25 percent voiced support for the Republican Party.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.

Cancer diagnostics startup wins top prize at annual Rice competition​

winner, winners

Rice University student-founded companies took home a total of $115,000 in equity-free funding at the annual Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge last week.

2025 Rice Innovation Fellow Alexandria Carter won the top prize and $50,000 for her startup Bionostic. The startup offers personalized diagnostics for cancer patients by using 3D culturing through its Advanced Tumor Landscape Analysis System (ATLAS) platform.

Carter is working toward her PhD in bioengineering in Professor Michael King's laboratory. She recently completed the Rice Innovation Fellows program and plans to commercialize ATLAS, according to a news release from Rice.

Actile Technologies, founded by another former Rice Innovation Fellow, Barclay Jumet, won second place and $25,000. The company is developing and commercializing textile-integrated technologies. InnovationMap first covered Jumet's wearable technology back in 2023.

Kairos took home the third-place prize and $15,000, plus the $2,000 audience choice award and the $5,000 undergraduate business award. Founded last year by Sanjana Kavula and Adhira Tippur, Kairos is an AI-powered patient intake platform built specifically for independent dental practices.

The NRLC features top startups founded by undergraduate, graduate and MBA students at Rice each year. The top three finishers were named among a group of five finalists earlier this year, which also included HAAST Autonomous and Project Kestrel.

HAAST is developing an unmanned aircraft for organ transport, while Kestrel uses machine learning to organize bird photographers’ photo collections.

Teams presented multiple five-minute pitches throughout the application process over Zoom and in-person before the five finalists presented at the NRLC Championships April 21 at the Rice Memorial Center. Each finalist walked away with an equity-free investment.


Other awards went to:

UnitCode

  • $5,000 MBA Venture Award

HAAST Autonomous

  • $2,500 Chan-Kang Family Prize for Bold Ambition
  • $1,000 Healthcare Innovations Prize

Telstar Networks

  • $2,500 Outstanding Undergraduate Startup Award

Multiplay

  • $1,500 Frank Liu Jr. Prize for Creative Innovation in Music, Fashion, & the Arts

Butterfly Books

  • $1,500 Social Impact Award

SOOZ

  • $1,000 Interdisciplinary Innovation Prize sponsored by OURI

Dooly

  • $1,000 Consumer Goods Prize

Project Kestrel

  • $1,000 AI Prize

Veloci Running won the NRLC last year for its naturally shaped running shoe. Founder and CEO Tyler Strothman recently told InnovationMap that the company has gone on to sell roughly 10,000 pairs of its flagship Ascent shoe, designed to relieve lower leg tightness and absorb impact. Read more here.